ReviewChemMedChem2026
Decoding Urease Inhibition: A Comprehensive Review of Inhibitor Scaffolds.
Review in ChemMedChem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Urease is a metalloenzyme produced by a wide range of organisms and plays a critical role in nitrogen microbial metabolism by catalyzing the hydrolysis of urea into ammonia and carbamic acid. High urease activity can lead to excessive ammonia levels, causing nitrogen loss from the soil, and also contributes as a virulent factor in some human pathogenic infections. Given its impact, urease inhibition has garnered significant attention in agriculture, environmental sciences, and medicine. Despite efforts to develop potent and selective inhibitors, discovering new agrochemicals and drugs faces significant challenges due to chemical and metabolic stability, lack of selectivity and toxicity, typically seen in urease inhibitors. As a result, extensive chemical diversity has been reported for urease inhibition and can lay the foundation for designing new inhibitors. Previous structure-activity relationship analyses have mainly focused on small subsets of compounds, leaving a broader comprehensive understanding across all known classes yet to be described. In an effort to support new exploratory strategies, this review provides a complete overview of the chemical landscape in urease inhibitors, covering more than 8000 compounds. We discuss current challenges, the biological and practical implications of urease inhibition and highlight potential scaffolds associated with activity. By exploring the diversity of reported inhibitors, we aim to identify broad activity patterns and gain deeper insights into activity relationships that govern inhibitory efficacy, paving the way for the future directions of finding new classes of urease inhibitors.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.